TRCT
AKTX

Tower Research Capital (TRC)’s Akari Therapeutics AKTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Hold
0
– -$22 – 5836
2023
Q4 		– Hold
0
– – – 5815
2016
Q4 		– Sell
-1
Closed -$7K – 3784
2016
Q3 		$7K Buy
+1
New +$7.8K ﹤0.01% 2297
2016
Q2 		– Hold
0
– – – 3490
2016
Q1 		– Sell
-1
Closed -$7K – 4048
2015
Q4 		$7K Hold
1
– – ﹤0.01% 2533
2015
Q3 		$23K Buy
+1
New +$11.8K ﹤0.01% 1602
2015
Q1 		– Hold
0
– -$3K – 4364
2014
Q4 		– Hold
0
– – – 3059
2014
Q3 		– Hold
0
– – – 3761
2014
Q2 		– Hold
0
– – – 2424
2014
Q1 		– Hold
0
– – – 3584

Other funds holding AKTX

OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $794M AUM 22.68% 1-Year Est. Return

Tower Research Capital (TRC)'s AKTX Position: Q1 2024 in Review

Tower Research Capital (TRC) held its Akari Therapeutics (AKTX) position steady in Q1 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5836.

Tower Research Capital (TRC) first reported a position in AKTX in Q3 2015 and has held it in 3 quarters since. The position peaked at $23K in Q3 2015. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2024.

  • Tower Research Capital (TRC) held 0 shares of Akari Therapeutics worth $0 as of Q1 2024.
  • Tower Research Capital (TRC) left its Akari Therapeutics share count unchanged in Q1 2024.
  • Akari Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2024, its #5836 holding.
  • Tower Research Capital (TRC) first reported a position in Akari Therapeutics in Q3 2015 and has held it in 3 quarters since.
  • Tower Research Capital (TRC)'s Akari Therapeutics position peaked at $23K in Q3 2015.
  • 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2024, filed 15 May 2024.